Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6862599 | 1.00 | TSHR (0.40) | TSHRTHRBEPHX2DNM1ALDH1A1 | |
| Octane SCHEMBL10951546 | 0.71 | TSHR (0.67) | TSHRTHRBEPHX2DNM1ALDH1A1 | |
| Octane SCHEMBL11688246 | 0.71 | TSHR (0.67) | TSHRTHRBEPHX2DNM1ALDH1A1 | |
| Hexane SCHEMBL28425185 | 0.67 | TSHR (0.58) | TSHRTHRBEPHX2DNM1ALDH1A1 | |
| SCHEMBL25381519 | 0.67 | LMNA (0.30) | TSHRLMNA | |
| SCHEMBL367967 | 0.66 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL1555632 | 0.66 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL1480046 | 0.66 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL17090779 | 0.66 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL17090793 | 0.66 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800777-B2 | HYDROCARBON WITH TERMINAL TRIALKYLSILANE ON ONE END AND A SILANE WITH AT LEAST ONE HYDROLYZABLE GROUP ON THE OTHER; BONDS TO CHROMATOGRAPHIC SUBSTRATE SUCH AS SILICA; MINIMAL ?PHASE COLLAPSE? | GELEST, INC. | 2004-10-05 | — | — | US | disclosed |
| US-20020173670-A1 | Trialkylsilanes for use in chromatographic applications, substrates including such compounds and methods of producing the same | GELSET, INC. | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173670-A1 | Trialkylsilanes for use in chromatographic applications, substrates including such compounds and methods of producing the same | PFAS, STS, ALK | TSHR 1261/4885THRB 1421/4885EPHX2 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.